Company intelligence / Profile preview

Acrivon Therapeutics, Inc.

Watertown, Massachusetts, United Statesacrivon.com ↗

Ownership: Public · ACRV
Employees: ~70
Development stage: Phase 2

Overview

Acrivon's lead candidate, ACR-368 (prexasertib), a selective small molecule inhibitor of CHK1/CHK2, has shown promising results in a registrational-intent Phase 2 trial. The company reported a confirmed objective response rate of approximately 50% in ovarian and endometrial cancers using its OncoSignature biomarker test to select patients. All responders remained on treatment at the time of reporting and median duration of response had not been reached. The company’s AP3 platform enables precise patient selection beyond genomics by matching drug mechanism to tumor biology[8][10].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

prexasertib

2 more assets in the full pipeline.

Request access →

Partnerships

In-license agreement with Eli Lilly for prexasertib; open to strategic co-development partnerships around AP3 and OncoSignature tests[10]

Financials

Market cap: $87.3M
Total revenue: $0
Enterprise value: $-528.5K

Beyond the preview

Go deeper on Acrivon Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acrivon Therapeutics, Inc..

Explore the full profile